Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.97 +3.59 (+19.53%)
Official Closing Price Updated: 4:15 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,730,547
Open 22.54
Bid (Size) 22.00 (73)
Ask (Size) 22.05 (4)
Prev. Close 18.38
Today's Range 20.94 - 22.86
52wk Range 16.88 - 150.48
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals. 
Via Benzinga

Performance

YTD
-82.3%
-82.3%
1 Month
+1.9%
+1.9%
3 Month
-59.2%
-59.2%
6 Month
-81.2%
-81.2%
1 Year
-85.0%
-85.0%

More News

Read More
AAR, Lucid Group, Monarch Casino & Resort And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts
Via Benzinga
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
What's going on in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult
Via Investor's Business Daily
Topics Death Earnings Government
Sarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy — Retail Eyes Rebound
Via Stocktwits
Topics Death
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
Via Chartmill
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 21.97
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 07/17/25 04:15 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.05B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS